Engene Holdings Inc (ENGN)

Aug 11, 2026, 11:00 AM EDT - 5 days ago

enGene Therapeutics Transcript: KOL event

Aug 11, 2026, 11:00 AM EDT - 5 days ago

enGene Therapeutics Slides: KOL event

Aug 4, 2026, 8:00 AM EDT - 12 days ago

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

2026-07-16T12:12:12.000Z - 4 weeks ago

enGene announces changes to board, appoints Heffernan as Chairman

Jul 16, 2026, 8:00 AM EDT - 4 weeks ago

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Jul 15, 2026, 9:00 AM EDT - 4 weeks ago

Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman

GERN

Jul 1, 2026, 8:00 AM EDT - 6 weeks ago

enGene Therapeutics Slides: Corporate presentation

2026-06-18T10:00:10.000Z - 2 months ago

enGene downgraded to Underweight from Equal Weight at Morgan Stanley

2026-06-16T10:06:52.000Z - 2 months ago

enGene price target lowered to $4 from $6 at H.C. Wainwright

2026-06-15T13:10:35.000Z - 2 months ago

enGene implements plan to reduce workforce by 50%

Jun 15, 2026, 9:00 AM EDT - 2 months ago

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

Jun 15, 2026, 9:00 AM EDT - 2 months ago

enGene Therapeutics Earnings release: Q2 2026

Jun 15, 2026, 9:00 AM EDT - 2 months ago

enGene Therapeutics Quarterly report: Q2 2026

Jun 9, 2026, 8:30 AM EDT - 2 months ago

enGene Therapeutics Transcript: AGM 2026

2026-05-14T15:24:03.000Z - 3 months ago

enGene price target lowered to $2 from $9 at UBS

2026-05-08T18:32:38.000Z - 3 months ago

Leerink downgraded enGene to Market Perform following LEGEND update

2026-05-08T16:22:56.000Z - 3 months ago

enGene downgraded to Perform from Outperform at Oppenheimer

2026-05-08T12:11:57.000Z - 3 months ago

enGene downgraded to Market Perform from Outperform at Leerink

May 8, 2026, 8:00 AM EDT - 3 months ago

enGene Therapeutics Proxy statement: Proxy filing

2026-05-08T09:16:27.000Z - 3 months ago

enGene downgraded to Outperform from Strong Buy at Raymond James

2026-05-08T09:15:51.000Z - 3 months ago

enGene downgraded to Neutral from Buy at Guggenheim

2026-05-08T09:10:12.000Z - 3 months ago

enGene downgraded to Neutral from Overweight at Piper Sandler

2026-05-08T09:00:14.000Z - 3 months ago

enGene downgraded to Market Perform from Outperform at Citizens

2026-05-08T00:55:12.000Z - 3 months ago

enGene downgraded to Equal Weight from Overweight at Wells Fargo

2026-05-07T22:42:47.000Z - 3 months ago

enGene downgraded to Equal Weight from Overweight at Morgan Stanley

2026-05-07T21:51:44.000Z - 3 months ago

enGene downgraded to Neutral from Buy at Guggenheim

May 7, 2026, 3:35 PM EDT - 3 months ago

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-05-07T14:15:38.000Z - 3 months ago

enGene announces updated interim results from LEGEND cohort

May 7, 2026, 8:00 AM EDT - 3 months ago

enGene Therapeutics Transcript: Study result

May 7, 2026, 8:00 AM EDT - 3 months ago

enGene Therapeutics Slides: Study result

May 7, 2026, 8:00 AM EDT - 3 months ago

enGene Therapeutics Press release: Study result

May 7, 2026, 7:00 AM EDT - 3 months ago

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

Apr 10, 2026, 7:00 AM EDT - 4 months ago

enGene Therapeutics Slides: Corporate presentation

Apr 7, 2026, 8:00 AM EDT - 4 months ago

enGene Announces Name Change to enGene Therapeutics Inc.

Mar 11, 2026, 1:40 PM EDT - 5 months ago

enGene Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 9:00 AM EDT - 5 months ago

enGene Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 9, 2026, 8:00 AM EDT - 5 months ago

enGene Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 7:00 AM EDT - 5 months ago

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mar 9, 2026, 7:00 AM EDT - 5 months ago

enGene Therapeutics Earnings release: Q1 2026

Mar 9, 2026, 7:00 AM EDT - 5 months ago

enGene Therapeutics Quarterly report: Q1 2026

Mar 9, 2026, 7:00 AM EDT - 5 months ago

enGene Therapeutics Slides: Corporate presentation

Feb 26, 2026, 1:20 PM EST - 6 months ago

enGene Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 20, 2026, 8:00 AM EST - 6 months ago

enGene to Participate in Upcoming Investor Conferences

Feb 19, 2026, 7:00 AM EST - 6 months ago

enGene Therapeutics Registration statement: Registration Filing

Feb 11, 2026, 2:30 PM EST - 6 months ago

enGene Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 8:00 AM EST - 6 months ago

enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 20, 2026, 5:35 PM EST - 7 months ago

enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

HTGC

Jan 9, 2026, 6:00 AM EST - 7 months ago

enGene Therapeutics Slides: Corporate presentation

Dec 22, 2025, 4:03 PM EST - 8 months ago

enGene Reports Full Year 2025 Financial Results and Provides Business Update

Dec 18, 2025, 4:00 PM EST - 8 months ago

enGene Therapeutics Annual report: Q4 2025

Dec 18, 2025, 4:00 PM EST - 8 months ago

enGene Therapeutics Earnings release: Q4 2025

Dec 2, 2025, 12:10 PM EST - 9 months ago

enGene Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 7:30 AM EST - 9 months ago

enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

Nov 25, 2025, 7:30 AM EST - 9 months ago

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 3:30 AM EST - 9 months ago

enGene Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 12:27 AM EST - 9 months ago

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

Nov 12, 2025, 4:01 PM EST - 9 months ago

enGene Announces Proposed Public Offering of Common Shares

Nov 12, 2025, 2:00 PM EST - 9 months ago

enGene Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 6:00 PM EST - 9 months ago

enGene Therapeutics Slides: Corporate Presentation

Nov 11, 2025, 12:30 PM EST - 9 months ago

enGene Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 12:30 PM EST - 9 months ago

enGene Therapeutics Slides: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 8:00 AM EST - 9 months ago

enGene Therapeutics Transcript: Study Update

Nov 11, 2025, 8:00 AM EST - 9 months ago

enGene Therapeutics Press release: Study Update

Nov 11, 2025, 8:00 AM EST - 9 months ago

enGene Therapeutics Slides: Study Update

Nov 11, 2025, 7:30 AM EST - 9 months ago

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Nov 11, 2025, 7:00 AM EST - 9 months ago

enGene Therapeutics Slides: Corporate Presentation

Nov 10, 2025, 4:05 PM EST - 9 months ago

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

Nov 4, 2025, 1:35 PM EST - 10 months ago

enGene Named a BioSpace 2026 Best Places to Work Winner

Oct 1, 2025, 4:03 PM EDT - 11 months ago

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sep 30, 2025, 7:30 AM EDT - 11 months ago

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

Sep 11, 2025, 4:03 PM EDT - 1 year ago

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

Sep 11, 2025, 9:30 AM EDT - 1 year ago

enGene Therapeutics Quarterly report: Q3 2025

Sep 11, 2025, 9:30 AM EDT - 1 year ago

enGene Therapeutics Earnings release: Q3 2025

Sep 10, 2025, 1:50 PM EDT - 1 year ago

enGene Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 8:45 AM EDT - 1 year ago

enGene Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 1 year ago

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

Jul 8, 2025, 8:00 AM EDT - 1 year ago

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

Jun 25, 2025, 8:00 AM EDT - 1 year ago

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

Jun 12, 2025, 8:00 AM EDT - 1 year ago

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 12, 2025, 8:00 AM EDT - 1 year ago

enGene Therapeutics Quarterly report: Q2 2025

Jun 12, 2025, 8:00 AM EDT - 1 year ago

enGene Therapeutics Earnings release: Q2 2025

Jun 4, 2025, 11:05 AM EDT - 1 year ago

enGene Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 8:30 AM EDT - 1 year ago

enGene Announces the Resignation of its Chief Medical Officer

May 29, 2025, 8:00 AM EDT - 1 year ago

enGene to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 7:30 AM EDT - 1 year ago

enGene Names Amy Pott as Chief Global Commercialization Officer

May 9, 2025, 8:00 AM EDT - 1 year ago

enGene Therapeutics Proxy statement: Proxy Filing

May 7, 2025, 11:30 AM EDT - 1 year ago

enGene Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 5, 2025, 2:00 PM EDT - 1 year ago

enGene Therapeutics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 8, 2025, 4:00 PM EDT - 1 year ago

enGene Therapeutics Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 1, 2025, 8:00 AM EDT - 1 year ago

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

Mar 11, 2025, 1:00 PM EDT - 1 year ago

enGene Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 10, 2025, 4:05 PM EDT - 1 year ago

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 10, 2025, 4:00 PM EDT - 1 year ago

enGene Therapeutics Quarterly report: Q1 2025

Mar 10, 2025, 4:00 PM EDT - 1 year ago

enGene Therapeutics Earnings release: Q1 2025

Mar 4, 2025, 8:00 AM EST - 1 year ago

enGene to Participate in the Leerink Partners Global Healthcare Conference

Feb 11, 2025, 8:40 AM EST - 1 year ago

enGene Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 4, 2025, 8:00 AM EST - 1 year ago

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 8:00 AM EST - 1 year ago

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

Dec 19, 2024, 4:05 PM EST - 1 year ago

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

Dec 19, 2024, 9:30 AM EST - 1 year ago

enGene Therapeutics Annual report: Q4 2024

Dec 19, 2024, 9:30 AM EST - 1 year ago

enGene Therapeutics Earnings release: Q4 2024

Dec 3, 2024, 3:00 PM EST - 1 year ago

enGene Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 10:00 AM EST - 1 year ago

enGene Therapeutics Transcript: JMP Hematology and Oncology Summit 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

enGene Therapeutics Registration statement: Registration Filing

Nov 13, 2024, 7:00 AM EST - 1 year ago

enGene Therapeutics Registration statement: Registration Filing

Nov 12, 2024, 10:30 AM EST - 1 year ago

enGene Therapeutics Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Oct 25, 2024, 8:00 AM EDT - 1 year ago

enGene Announces $60 Million Private Placement Financing

Oct 22, 2024, 4:05 PM EDT - 1 year ago

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Oct 21, 2024, 8:45 AM EDT - 1 year ago

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Sep 26, 2024, 6:30 AM EDT - 2 years ago

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

Sep 11, 2024, 9:30 AM EDT - 2 years ago

enGene Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 4:33 PM EDT - 2 years ago

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

Sep 10, 2024, 4:00 PM EDT - 2 years ago

enGene Therapeutics Quarterly report: Q3 2024

Sep 10, 2024, 4:00 PM EDT - 2 years ago

enGene Therapeutics Earnings release: Q3 2024

Sep 6, 2024, 11:00 AM EDT - 2 years ago

enGene Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 4:50 PM EDT - 2 years ago

enGene Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Jul 24, 2024, 4:05 PM EDT - 2 years ago

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jul 24, 2024, 6:30 AM EDT - 2 years ago

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

Jun 14, 2024, 7:01 AM EDT - 2 years ago

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

Jun 14, 2024, 7:00 AM EDT - 2 years ago

enGene Therapeutics Quarterly report: Q2 2024

Jun 14, 2024, 7:00 AM EDT - 2 years ago

enGene Therapeutics Earnings release: Q2 2024

Jun 5, 2024, 12:30 PM EDT - 2 years ago

enGene Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

May 15, 2024, 4:05 PM EDT - 2 years ago

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

May 2, 2024, 4:05 PM EDT - 2 years ago

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

Apr 18, 2024, 8:00 AM EDT - 2 years ago

enGene Therapeutics Proxy statement: Proxy Filing

Apr 9, 2024, 8:56 AM EDT - 2 years ago

/C O R R E C T I O N -- enGene Inc./

Apr 9, 2024, 8:00 AM EDT - 2 years ago

enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development